Jason Harris | Authors


Frontline Venetoclax and Obinutuzumab Maintains Delay of Progression in CLL

June 15, 2021

With further follow-up from the phase 3 CLL14 trial, the median progression-free survival was still reached with the fixed-dose regimen of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.

Durable Responses Seen with Cilta-Cel at 18 Months in Relapsed/Refractory Multiple Myeloma

June 08, 2021

Sustained efficacy and durable responses was seen with Ciltacabtagene autoleucel, an investigational B-cell maturation antigen-directed CAR T-cell therapy, in heavily pretreated patients with relapsed/refractory multiple myeloma.